Loading clinical trials...
Loading clinical trials...
A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
Conditions
Interventions
Rilvegostomig
Cisplatin
+5 more
Locations
105
United States
Research Site
Phoenix, Arizona, United States
Research Site
Santa Rosa, California, United States
Research Site
Jacksonville, Florida, United States
Research Site
Baltimore, Maryland, United States
Research Site
Detroit, Michigan, United States
Research Site
Rochester, Minnesota, United States
Start Date
November 24, 2025
Primary Completion Date
February 23, 2029
Completion Date
February 23, 2029
Last Updated
March 30, 2026
NCT06955988
NCT06581419
NCT05450692
NCT02855125
NCT05132777
NCT04448379
AstraZeneca Clinical Study Information Center
CONTACT
1-877-240-9479information.center@astrazeneca.comLead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions